Summary Haematoporphyrin derivative (HPD) photodynamic therapy (PDT) may have clinicial application in the management of patients with retinoblastoma. Heterotransplantation of retinoblastoma cells into the anterior chamber of the nude mouse eye and the subsequent growth of small tumour masses has provided a model for evaluation of various therapeutic modalities. Ninety-four evaluable xenograft tumours in 54 nude mice were randomized to receive one of the following treatments: cyclophosphamide (CPM) alone, HPD-PDT alone, CPM followed by HPD-PDT, HPD-PDT followed by CPM, or (White, 1983c) . Although RB is highly curable by enucleation and/or radiotherapy, the morbidity of current treatment has made HPD-PDT an appealing prospect in the management of early, and particularly bilateral RB. The relatively easy access of light to the intraocular lesion (Gomer et al., 1984) and documented in-vitro responsiveness of RB to HPD-PDT (Sery, 1979) have encouraged further research.
Haematoporphyrin derivative (HPD) photodynamic therapy (PDT) is being applied to the treatment of malignancy in an increasing number of clinical and experimental situations. Retinoblastoma (RB) is the most frequently encountered eye cancer in childhood and is bilateral in one third of cases (White, 1983c) . Although RB is highly curable by enucleation and/or radiotherapy, the morbidity of current treatment has made HPD-PDT an appealing prospect in the management of early, and particularly bilateral RB. The relatively easy access of light to the intraocular lesion (Gomer et al., 1984) and documented in-vitro responsiveness of RB to HPD-PDT (Sery, 1979) have encouraged further research.
A xenograft model has been developed whereby human RB can be studied heterotransplanted into the anterior chamber of the nude (athymic) mouse eye (Gallie et al., 1977) . Necrosis was documented histologically in very advanced tumours after HPD injection followed by PDT in the mouse (Benedict et al., 1980b) . The model was adapted to allow the study of early, small tumours in situ and document changes in growth pattern as a measure of responsiveness (White et al., 1983a) . Various chemotherapeutic agents have been successfully tested in this adapted model (White et al., 1983b) . Cyclophosphamide (CPM) was the most effective of the currently available chemotherapeutic agents. Given this background, a series of experiments were performed to evaluate responsiveness of RB to HPD-PDT and the potential interaction between chemotherapy and HPD-PDT in the model. It became apparent that poor vascularization of the xenograft played an important role in determining response to HPD-PDT.
Materials and methods
The model A number of human RB cell lines have been established and maintained by the heterotransplantation of cells from enucleated eyes of children with RB (Benedict et al., 1980a) . Cells in suspension (105 ml-1) were injected under microscopic visualization directly into the anterior chamber of the mouse eye (total volume injected less than 5 microlitres). Swiss background nude (athymic) mice of both sexes were utilized. The animals were maintained and treated in a protected, sterile environment and were allowed food and water ad libitum. Their weight was monitored weekly. In the model, tumour growth is usually observed after a latency of 3-4 weeks and can then be monitored to progress until the front of the eye is filled by RB. The tumour is graded 1-4 according to the proportion of the anterior chamber filled by RB. As the volume of the anterior chamber is estimated to be 4-8 pl, a grade I tumour, occupying one quarter of that space, would be expected to have a volume of 1-2 p1. Grade 2 (2 quarters) is 2-4 u1, grade 3 (3 quarters) is 3-6 pl and grade 4 is 4-8 pl, or more due to expansion by the tumour. In therapeutic assays treatment is commenced when a tumour is graded 1 or 2 (Figure 1) 
Mouse treatment experiments
Fifty-four nude mice bearing 94 evaluable tumours (40 mice bilateral tumours, 14 mice unilateral tumours), derived from the LARB-69 xenograft line (Benedict et al., 1980a) were randomized into one of 5 treatment groups (Table I) one week later by CPM as in group 1. Group 5 acted as controls and were given i.p. saline.
HPD-PDT cytotoxicity to cells in culture
The LARB-69 cells were grown in a culture system designed for the maintenance of RB cells in vitro and previously published (Bogenmann et al., 1983) . In brief, a suspension of RB cells (single cells and small clumps) were prepared from in vivo tumours and plated onto 20 dishes containing cultured rat smooth muscle cells (SMC) as substrate. The culture medium consisted of DMEM (Dulbecco's modified Eagle medium, Grand Island Biological Co., Santa Clara, CA) supplemented with 10% human serum, 100U penicillin ml-1, 100 Mg steptomycin ml-I and 4mM glutamine, and was changed every third day. After 6 days, growth was established in chains and aggregates of RB cells. Since the attachment to the SMC was loose, they were then readily dissociated into suspension with DMEM and 1% foetal calf serum (FCS) by pipetting.
After 2 washes, the cells were resuspended and aliquoted into 20 equal one ml volumes in DMEM and 1% FCS. Four aliquots were replated untreated onto the SMC culture system as described. The remaining 16 ml were incubated with HPD, 30 jg ml-1, in 37°C, for 1 h, in darkness and then washed twice to remove unbound HPD. Sixteen 60 mm Petri dishes were plated (one ml each) and exposed to red light as follows: 4 aliquots min, 4 aliquots 3 min, 4 aliquots 10 min, and 4 aliquots were kept in darkness as further control. Subsequently, the cells were replated onto the SMC culture system and all 20 dishes were monitored daily (day 3-7) for cell growth and viability. Dishes were kept in darkness.
Comparative viability was assessed by serial direct observation of cell growth in all dishes as a function of time.
The light source used was a parallel series of soft white, 30 watt, fluorescent bulbs (Sylvania, F30T12), enclosed on top with a sheet of clear plexiglass filtered with a milar film (Rubylith SR-3, Ulano Corp., Brooklyn, NY) as previously published (Gomer et al., 1983) . A treatment stand allowed the dishes to be placed 5cm above the light source. The light intensity at the treatment site was 0.35 mW cm-2 and the delivered spectrum was 570 nm to 650 nm with a peak output at 620 nm.
Results

Mouse treatment experiments
In Table I HPD-PDT cytotoxicity to cells in culture Daily observations of the 20 dishes in culture revealed viable cells for up to 7 days after treatment in the 'no HPD-no PDT' controls (4 plates), in the 'yes HPD-no PDT' controls (4 plates), and in the 4 plates exposed to light for only 1 min. However, no viable cells were identified by day 3 after treatment in the dishes where exposure to light had been continued for 3min (4 dishes) or 10min (4 dishes).
Discussion
The model reliably demonstrated the responsiveness of RB to CPM. This serves as a positive control in the therapeutic experiments. On the other hand, HPD-PDT did not influence tumour growth in any of the three treatment groups where it was included.
The most likely explanation for failure of response to HPD-PDT of the human RB in this xenograft is poor vascularization of early, small tumours grown in the anterior chamber of the mouse eye. We have been able to document in histologic specimens of eyes enucleated at the various grades that early growth occurs as an avascular cluster or nodule of RB cells (Figure 2) . Subsequent vascularization occurs as tumour begins to fill the anterior chamber (grade 4) and accounts for the histologic responses in advanced tumours of LARB-69 and other RB cell origin, reported in prior studies (Benedict et al., 1980b ). In the current experiment, when tumours progressed to grade 4 we were able to confirm increased necrosis after exposure to HPD-PDT, relative to untreated tumours of the same grade, even in eyes that had proved resistant at an earlier grade of growth. However, early tumours removed and examined histologically after HPD-PDT showed only minimal centrilobular necrosis, consistent with that same finding in totally untreated tumours.
It was important to further confirm that the LARB-69 used in these experiments had not acquired HPD-PDT resistance. For this reason, in vitro treatment was carried out and response was documented. With this limited aim, the in vitro data are purely comparative and no quantitative profile of cell growth was obtained. Although a number of variables limit the direct comparison of the in vitro system to the intraocular model, one can at least conclude that the LARB-69 cells were sensitive to HPD-PDT in vitro in a manner and to a degree similar to other cultured cells. In fact, there has not been documentation of any cell line totally resistant to HPD-PDT in culture.
Although the poor vascularity of early tumour growth is implicated in the failure of HPD-PDT, it was important to exclude the possibility that the mechanism is entirely due to the peculiarity of the model, viz. that there is no access of HPD to the tumour cells via the aqueous fluid in the anterior chamber. We have been able to show by fluorescent photography that HPD is present in the early tumour, albeit not preferentially concentrated by comparison to surrounding tissues (Figure 1 ). These tissues are hypopigmented in the nude mouse and readily demonstrate the presence of HPD fluorescence. In prior studies we have analysed the distribution of 3H-HPD in nude mice (Gomer et al., 1982) . Eyes with tumours had up to four fold increased concentration 3H-HPD than control eyes (tumours were too small to be measured independently). Furthermore, recent data utilising a larger, rabbit model demonstrated that HPD measured by fluorescence is present maximally in vascular ocular structures (iris, choroid, vascularised tumour), is absent in avascular structures (lens, cornea, vitreous), but is also detectable in the aqueous fluid (Gomer et al., 1985) . It (Parrish, 1983) . 'Leaky' vasculature may allow HPD to enter the extracellular fluid space and in this regard it is noteworthy that tumour vasculature may be 'leakier' than normal (Straight et al., 1985) . Furthermore, tumours may lack the mechanism required to efficiently clear the HPD retained therein (Bugelski et al., 1981) . Bugelski has shown in autoradiographic studies that 3H-HPD was distributed at a ratio of 5:1 in favour of the vascular stroma in experimental animal models and that vascular damage occurred within 15 minutes after HPD-PDT (Bugelski et al., 1981) .
Although tissue hypoxia may have a role in the mechanism of vascular effects, the oxygen tension required for response to HPD-PDT (rather than cure) is small. Furthermore, in our model continued tumour growth was documented, chemotherapeutic agents were effective and radiation therapy has also been shown to produce a response (Gallie et al., 1982) . It is unlikely, therefore, that oxygen tension was a limiting factor.
The most challenging hypotheses suggest that the primary target for HPD-PDT tumour kill is the vascular endothelial cell rather than the tumour cell itself. Evidence in favour of a vascular collapse being the initial event in PDT induced tumour necrosis has been advanced by various workers based on observations in both human and animal tumour studies (Bugelski et al., 1981; Bicher et al., 1981; Selman et al., 1985; Henderson et al., 1985; Straight et al., 1985) . Elegant in vitro models have confirmed these observations and have strengthened the arguments in favour of a primary vascular mechanism (Star et al., 1984; Straight et al., 1985) .
Henderson was able to demonstrate that clonogenicity of tumour cells following HPD-PDT was proportionate to the time the cells remain in situ before being excised and plated. Therefore, a 10 hour delay in excision produced a one hundred fold reduction in clonogenicity, a finding comparable to that produced by vascular deprivation due to death of the host (Henderson et al., 1984) . Berenbaum et al. (1986) have produced convincing evidence for a primary endothelial site of action intracranially, a particularly important finding in view of the expected barriers to penetration of HPD and other chemicals into the brain and brain tumours. Furthermore, authors have expressed doubts regarding the often quoted view that tumours and therefore tumour cells have the capacity to preferentially retain HPD (Straight et al., 1985; Winkelmen et al., 1985) .
Several of the mechanisms suggested for the role of tumour vascularity in HPD-PDT effectiveness may be relevant to the model utilized in our studies. In the knowledge that failure of delivery of HPD was not solely responsible and that the same cells in a vascular situation are responsive to the same treatment, we are able to add to the body of evidence that tumour vascularity may play a pivotal and possibly primary role in HPD-PDT. The ability to achieve photo-cytotoxicity in vitro with this cell-line, as in others, points to multiple, dose dependent mechanisms of HPD-PDT effect. It is likely that in high concentrations HPD-PDT is photocytotoxic directly to tumour cells, while in vivo tumour kill may depend to variable degrees on the role of the vascular endothelium as a primary target.
